Squarepoint
ASND icon

Squarepoint’s Ascendis Pharma A/S ASND Stock Holding History

Squarepoint’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.3M Buy
+5,700
New +$1.28M ﹤0.01% 2549

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Squarepoint's ASND Position: Q1 2026 in Review

Squarepoint sold out of Ascendis Pharma A/S (ASND) in Q1 2026, closing a stake of 6,474 shares — an estimated $1.45M sold.

Squarepoint first reported a position in ASND in Q1 2018 and held it in 16 quarters. The position peaked at $1.79M in Q3 2022. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

  • Squarepoint reported no remaining Ascendis Pharma A/S position as of Q1 2026 after selling out during the quarter.
  • Squarepoint sold 6,474 Ascendis Pharma A/S shares in Q1 2026, an estimated $1.45M.
  • Squarepoint first reported a position in Ascendis Pharma A/S in Q1 2018 and held it in 16 quarters.
  • Squarepoint's Ascendis Pharma A/S position peaked at $1.79M in Q3 2022.
  • 273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.